3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Resectable MMR-deficient Solid Tumors
1
Interventions
balstilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Resectable MMR-deficient Solid Tumors
×
balstilimab
×
Clear all
NCT06279130
2026-03-05
NEOASIS
The Netherlands Cancer Institute
Phase 2/3
Recruiting
133 enrolled